`Q1 2012
`Q2
`Q3
`Q4
`Q1 2013
`Q2
`Q3
`Q4
`Q1 2014
`Q2
`Q3
`Q4
`Q1 2015
`Q2
`Q3
`Q4
`Q1 2016
`Q2
`Q3
`Q4
`Q1 2017
`Q2
`Q3
`Q4
`Q1 2018
`Q2
`Q3
`Q4
`Q1 2019
`Q2
`Q3
`Q4
`Q1 2020
`Q2
`Q3
`Q4
`Q2 2021
`
`AVASTIN
`63%
`57%
`58%
`53%
`48%
`46%
`48%
`46%
`48%
`49%
`48%
`47%
`44%
`46%
`45%
`43%
`45%
`47%
`46%
`45%
`43%
`46%
`43%
`44%
`46%
`43%
`40%
`43%
`40%
`41%
`41%
`40%
`45%
`43%
`39%
`43%
`41%
`39%
`
`LUCENTIS
`37%
`32%
`28%
`27%
`30%
`30%
`29%
`27%
`26%
`25%
`26%
`26%
`26%
`22%
`24%
`26%
`22%
`19%
`19%
`19%
`22%
`19%
`18%
`18%
`17%
`20%
`19%
`19%
`19%
`18%
`19%
`17%
`13%
`13%
`15%
`14%
`14%
`14%
`
`EYLEA
`0%
`11%
`14%
`20%
`21%
`24%
`23%
`26%
`25%
`25%
`26%
`27%
`30%
`32%
`31%
`32%
`34%
`35%
`35%
`34%
`35%
`35%
`39%
`38%
`37%
`37%
`41%
`38%
`41%
`41%
`40%
`43%
`39%
`39%
`41%
`39%
`40%
`44%
`
`Brolucizumab
`
`3%
`5%
`5%
`4%
`5%
`3%
`
`Samsung et al. v. Regeneron IPR2023-00884
`Regeneron Pharmaceuticals, Inc. Exhibit 2231 Page 1
`
`